Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

The company is poised to grow, even if it must shut down its compounded GLP-1 agonist business. The stock's valuation is jaw-droppingly cheap for what the business is already doing without GLP-1 ...

Register for BNC#7 here. GLP-1 receptor agonists are revolutionizing health care, moving beyond diabetes and obesity to treat cardiovascular, kidney, and possibly neurodegenerative diseases. As usage ...

Glucagon-like agonists (GLP-1s ... The success that some achieve using GLP-1s can come with a price – both financially and ...

Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in those with type 2 diabetes. The prescribing ...

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for ...